Alaunos Therapeutics reports Q3 EPS (4c) vs (4c) last year

Reports Q3 revenue $0 vs $2.911M last year. The Company continues to explore strategic alternatives, which may include but are not limited to, an acquisition, merger, reverse merger, sale of assets, strategic partnerships, capital raises or other transactions. In connection with the strategic reprioritization, the Company has reduced its workforce by approximately 80% to date in order to streamline the organization and to maximize its cash runway.